Consistently, c-Myc upregulation reverts the therapeutic effect of BET inhibitors on pancreatic cancer and is responsible for resistance to BET inhibitors.160–162 BET inhibitors such as I-BET762 could lead to pancreatic cancer cell cycle arrest in G0/G1 phase and inhibit the proliferation and metastasis of pancreatic cancer cells. Here, MYC is linked to familial pancreatic carcinoma.